Sugi Predict

Sugi Predict / Compounds / SCHEMBL47275

SCHEMBL47275

SCHEMBL47275

CC(=O)N[C@H](CO)C(=O)NCc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.74
▸ CA1 P00915 1/20 0.74
▸ CA2 P00918 1/20 0.74
▸ CA3 P07451 1/20 0.74
▸ CA4 P22748 1/20 0.74
▸ CA6 P23280 1/20 0.74
▸ CA5A P35218 1/20 0.74
▸ CA7 P43166 1/20 0.74
▸ CACNA1C Q13936 1/20 0.74
▸ SCN9A Q15858 1/20 0.74
▸ CA9 Q16790 1/20 0.74
▸ CA13 Q8N1Q1 1/20 0.74
▸ CA14 Q9ULX7 1/20 0.74
▸ CA5B Q9Y2D0 1/20 0.74
▸ ALDH1A1 P00352 1/20 0.63
▸ MMP8 P22894 3/20 0.62
▸ CTSS P25774 1/20 0.57
▸ CTSK P43235 1/20 0.57
▸ EGFR P00533 1/20 0.56
▸ SRC P12931 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8205298 1.00 CA12 (0.74) CA12CA1CA2CA3CA4
SCHEMBL1697369 1.00 CA12 (0.74) CA12CA1CA2CA3CA4
SCHEMBL1895974 0.88 CA1 (0.70) CA12CA1CA2CA3CA4
SCHEMBL12240240 0.88 CA12 (0.74) CA12CA1CA2CA3CA4
SCHEMBL2742289 0.88 CA12 (0.74) CA12CA1CA2CA3CA4
SCHEMBL2606494 0.88 CA12 (0.74) CA12CA1CA2CA3CA4
SCHEMBL12840933 0.87 CA12 (0.62) CA12CA1CA2CA3CA4
SCHEMBL20720018 0.87 MMP8 (0.61) CA12CA1CA2CA3CA4
SCHEMBL12505312 0.87 MMP8 (0.61) CA12CA1CA2CA3CA4
SCHEMBL7356728 0.86 CA12 (0.72) CA12CA1CA2CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119335094-A Reversed-phase liquid chromatography method for detecting lacosamide dry syrup related substances 海南卫康制药(潜山)有限公司 2025-01-21 — — CN claimed
CN-118271200-A Industrial preparation method and application of lacosamide 北京澳合药物研究院有限公司 2024-07-02 — — CN claimed
CN-107641087-A A kind of preparation method for industrializing scheme for lacosamide 合肥远志医药科技开发有限公司 2018-01-30 — — CN claimed
US-9242926-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2016-01-26 — — US claimed
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 — — US claimed
US-20140296572-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2014-10-02 — — US claimed
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES PRIVATE LIMITED (IN) 2013-02-14 — — US claimed
EP-2534127-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN Laboratories Limited (IN) 2012-12-19 — — EP claimed
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-08-16 — — US claimed
WO-2011130615-A2 PREPARATION OF LACOSAMIDE DR. REDDY'S LABORATORIES LTD. (IN) 2011-10-20 — — WO claimed
WO-2011099033-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES LIMITED (IN) 2011-08-18 — — WO claimed
CN-119707727-A Lacosamide Process for the preparation of amines 浙江华海药业股份有限公司 2025-03-28 — — CN disclosed
CN-119405599-A Lacosamide injection and preparation method thereof 常州市第四制药厂有限公司 2025-02-11 — — CN disclosed
CN-119335094-A Reversed-phase liquid chromatography method for detecting lacosamide dry syrup related substances 海南卫康制药(潜山)有限公司 2025-01-21 — — CN disclosed
CN-118271200-A Industrial preparation method and application of lacosamide 北京澳合药物研究院有限公司 2024-07-02 — — CN disclosed
US-6133261-A THERAPEUTIC METHOD FOR TREATING OR PREVENTING STROKE AND OTHER ISCHEMIC DISORDERS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 2000-10-17 — — US disclosed
EP-1038522-A2 Anticonvulsant enantiomeric amino acid derivatives Research Corporation Technologies, Inc (US) 2000-09-27 — — EP disclosed
EP-0888289-A1 ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES Research Corporation Technologies, Inc (US) 1999-01-07 — — EP disclosed
US-5773475-A DIPEPTIDES FOR CENTRAL NERVOUS SYSTEM DISORDERS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1998-06-30 — — US disclosed
WO-1997033861-A1 ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1997-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120209022-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CA3, TREH, NAAA CA12 31/4885CA1 9/4885CA2 32/4885
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE AMY1A, PTMA, NAAA CA12 3088/4885CA1 1930/4885CA2 3258/4885
US-20140296572-A1 PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF CA3, TREH, NAAA CA12 31/4885CA1 9/4885CA2 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.